January 6, 2025 Sophia Vida
Breaking News

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Medicare coverage expanded following study showing that monitoring with Oncocyte’s assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (DSA) MolDX confirms eligibility for billing under current Local Coverage Determination (LCD) and Z-Code Up to 20% of patients will have detectable DSA within the first five years post kidney transplant, … Continue reading “Oncocyte Expands Market Opportunity for VitaGraft™ Kidney”